 |
|
|
| |
OUTCOMES FOR WOMEN RECEIVING LONG-ACTING CABOTEGRAVIR + RILPIVIRINE MONTHLY AND EVERY 2 MONTHS: ATLAS-2M STUDY WEEK 48 RESULTS
|
| |
| |
Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
Paul Benn,1 Romina Quercia,1 Krischan Hudson,2 Yuanyuan Wang,3 Vasiliki Chounta,1 Christine Talarico,2
Susan Ford,2 Amy Cutrell,2 David A. Margolis,2 Rodica Van Solingen-Ristea,4 Simon Vanveggel,4 Veerle Van Eygen,4 Joseph W. Polli,2 Annemiek de Ruiter,1 Kimberly Smith,2 William R. Spreen2
1ViiV Healthcare, Brentford, UK; 2ViiV Healthcare, Research Triangle Park, NC, USA; 3GlaxoSmithKline, Collegeville, PA, USA;
4Janssen Research & Development, Beerse, Belgium
|
| |
|
|
|
|
|
